Skip to content

For Canadian Residents Only

Sanofi

Sarclisa (isatuximab)

English Français

What is SARCLISA®?1

SARCLISA®: What It Does and How It Works 

SARCLISA® is used to treat multiple myeloma in patients who have received treatments for multiple myeloma before. It is used together with two other combinations of medicines: 

  • pomalidomide and dexamethasone; or 
  • carfilzomib and dexamethasone

SARCLISA® is a cancer medicine that contains the active substance isatuximab (ee-sah-TUKS-i-mab). It belongs to a group of medicines called “monoclonal antibodies.” Monoclonal antibodies, such as SARCLISA®, are proteins that have been designed to recognize and attach themselves to a target substance. In the case of SARCLISA®, the target is a substance called “CD38” that is found on cells of multiple myeloma, a cancer of the plasma cells, which are found in your bone marrow. By attaching to multiple myeloma cells, the medicine helps the natural defences of your body (immune system) identify and destroy them.

Your healthcare team, as well as the REACH™ Patient Support Program team, will be available to answer any questions you may have.

Reference

  1. PrSARCLISA® Product Monograph. Sanofi Canada. January 12, 2024.

Please Read and Accept the Terms of Use

To enter the site, please confirm you have read and agreed to the terms and conditions below.

Terms of Use

Sanofi operates in Canada through affiliated companies including sanofi-aventis Canada Inc., Sanofi Pasteur Limited and Sanofi Consumer Health Inc. (collectively referred to as “Sanofi Canada”). Sanofi Canada maintains this Website (the “Website”) for your personal information, education and communication. Please feel free to browse the Website.

Through your access and use of the Website, you accept, without limitation or qualification, the terms and conditions (“Terms & Conditions”) set forth at https://www.sanofi.ca/en/terms-conditions and our Privacy Policy, found at https://www.sanofi.ca/en/privacy-policies, incorporated herein by reference. If you do not agree to these Terms & Conditions or the Privacy Policy, you must not access or use the Website.

Please read and accept the Terms of Use before entering the website.